Michael Salzmann was selected in the LSIPR 50 2017 publication for his influence on the life sciences industry. He featured in the business and innovation section, as LSIPR reports.
Name: Michael Salzmann
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’.
LSIPR 50 2017, Michael Salzmann, Neurimmune, human monoclonal antibody, biopharma, therapeutics, Alzheimer's, Parkinson's